Vibegron, sold under the brand name Gemtesa, is a medication for the treatment of overactive bladder.
| FactSnippet No. 626,572 |
12 Facts About Vibegron
2.
Vibegron is a selective beta 3 adrenergic receptor agonist.
| FactSnippet No. 626,573 |
3.
Vibegron is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
| FactSnippet No. 626,574 |
4.
Vibegron is a selective beta3AR agonist that is developed in Japan by Kyorin Pharmaceutical Co.
| FactSnippet No. 626,575 |
5.
Vibegron has been proven effective in 5 key clinical trials.
| FactSnippet No. 626,576 |
6.
Vibegron was approved for medical use in the United States in December 2020.
| FactSnippet No. 626,577 |
7.
Vibegron is a selective agonist for the beta-3 adrenergic receptor.
| FactSnippet No. 626,578 |
8.
Vibegron was evaluated in patients with overactive bladder in several clinical studies.
| FactSnippet No. 626,579 |
9.
Vibegron is in contrast to other OAB drugs very selective and leads to a lesser degree in unwanted side effects.
| FactSnippet No. 626,580 |
10.
Vibegron is found to be a substrate for CYP3A4 in vivo, but does not actually induce or inhibit any of the cytochrome P450 enzymes and is thus less likely to take part in drug–drug interactions.
| FactSnippet No. 626,581 |
11.
Apart from the no to little DDIs, Vibegron has an additional safety quality in that it does not cross the blood-brain barrier and therefore does not induce cognitive impairment.
| FactSnippet No. 626,582 |
12.
Furthermore, Vibegron can be taken with or without food, this does not have an effect on vibegron plasma concentrations.
| FactSnippet No. 626,583 |